Alibaba Health Information Technology Limited
ALBHF
Other OTC0.58
USD
+0.16
- -
ISIN
BMG0171K1018
CUSIP
G0171K101
Return %
Stock
S&P500
1Y
3.73
18.46
3Y
-7.91
64.72
5Y
-68.76
72.79
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Difan Shen
- Full Time Employees
- 1,429
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Tower One Causeway Bay Hong Kong
- IPO Date
- Jul 20, 2018
- Website
- alihealth.cn
- Similar Companies
- Business
- Alibaba Health Information Technology Limited (ALBHF) is an investment holding company and the flagship healthcare platform of Alibaba Group, providing integrated online and offline medical and healthcare solutions primarily in Mainland China and Hong Kong. The company engages in pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services, offering prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and other health-related items through self-operated B2C retail, Tmall Healthcare Platform with over 97 million SKUs from more than 56,000 merchants, and offline pharmacy outlets accessible via Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark; it also delivers medical and healthcare services such as medical checkups, consultations, appointment booking, vaccination, dental and mental care, optometry, nursing, and traditional Chinese medicine via internet hospitals and over 250,000 contracted licensed professionals, alongside digital tracking via the "Ma Shang Fang Xin" platform for pharmaceuticals, medical devices, and consumables. Incorporated in 1998 and headquartered in Causeway Bay, Hong Kong, the company, formerly CITIC 21CN Company Limited, rebranded to Alibaba Health Information Technology Limited in September 2014. In recent developments, Alibaba Health reported interim revenue of RMB16.7 billion and net profit of RMB1.3 billion for the six months ended September 30, 2025, reflecting 17% and 65% year-on-year growth, respectively, driven by 19% expansion in pharmaceutical direct sales to RMB14.4 billion; it formed strategic partnerships including a comprehensive agreement with United Imaging Microelectronics in April 2025 for medical-grade hearing aids, collaborations with Innovent Biologics in August 2025 for Mazdutide disease management and supply chain, and with Simcere Pharmaceutical in September 2025 for Daridorexant insomnia solutions, while Alibaba Group issued HK$12 billion in exchangeable bonds into Alibaba Health shares in July 2025 and the company advanced AI applications in e-commerce and clinical care.
Alibaba Health Information Technology (OTC:ALBHF) Shares Down 6.4% – What’s Next?
Alibaba Health Information Technology (OTC:ALBHF) Shares Up 2.1% – Here’s What Happened
Alibaba Health Information Technology (OTC:ALBHF) Shares Down 5.1% – Here’s Why